KalVista Pharmaceuticals Toekomstige groei

Future criteriumcontroles 5/6

De verwachting is dat KalVista Pharmaceuticals de winst en omzet met respectievelijk 61.3% en 52.4% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 63.5% per jaar.

Belangrijke informatie

61.3%

Groei van de winst

63.5%

Groei van de winst per aandeel

Biotechs winstgroei	28.3%
Inkomstengroei	52.4%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Good
Laatst bijgewerkt	04 Nov 2024

Recente toekomstige groei-updates

Recent updates

Is KalVista Pharmaceuticals (NASDAQ:KALV) In A Good Position To Deliver On Growth Plans?

Sep 12

KalVista Pharmaceuticals: Looking To Be A Major Player In HAE

Sep 05

Bullish On KalVista Pharmaceuticals: Sebetralstat Nears Approval, Aiming For 2025 Launch

Jun 24

KalVista: Positive Results From Phase 3 Trial Pave The Way For Commercialization (Downgrade)

Feb 14

We're Keeping An Eye On KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Rate

Jan 30

We're Keeping An Eye On KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Rate

Oct 04

We Think KalVista Pharmaceuticals (NASDAQ:KALV) Needs To Drive Business Growth Carefully

May 02

KalVista: Another Setback But The Key Value Driver Is Still In Place

Oct 14

Here's Why We're Watching KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Situation

Sep 24

Is KalVista Pharmaceuticals (NASDAQ:KALV) In A Good Position To Invest In Growth?

May 18

Companies Like KalVista Pharmaceuticals (NASDAQ:KALV) Are In A Position To Invest In Growth

Feb 02

We Discuss Why KalVista Pharmaceuticals, Inc.'s (NASDAQ:KALV) CEO Compensation May Be Closely Reviewed

Sep 24

We're Hopeful That KalVista Pharmaceuticals (NASDAQ:KALV) Will Use Its Cash Wisely

Jul 02

Winst- en omzetgroeiprognoses

NasdaqGM:KALV - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
4/30/2027	174	-7	-48	23	5
4/30/2026	80	-109	-141	-93	7
4/30/2025	20	-155	-170	-151	7
7/31/2024	N/A	-142	-103	-103	N/A
4/30/2024	N/A	-127	-90	-89	N/A
1/31/2024	N/A	-108	-97	-97	N/A
10/31/2023	N/A	-101	-79	-78	N/A
7/31/2023	N/A	-95	-80	-79	N/A
4/30/2023	N/A	-93	-76	-75	N/A
1/31/2023	N/A	-91	-81	-79	N/A
10/31/2022	N/A	-92	-86	-84	N/A
7/31/2022	N/A	-89	-85	-83	N/A
4/30/2022	N/A	-82	-79	-78	N/A
1/31/2022	N/A	-73	-63	-62	N/A
10/31/2021	N/A	-61	-57	-56	N/A
7/31/2021	N/A	-52	-45	-44	N/A
4/30/2021	N/A	-46	-30	-30	N/A
1/31/2021	4	-38	-32	-32	N/A
10/31/2020	5	-37	-37	-37	N/A
7/31/2020	9	-33	-37	-37	N/A
4/30/2020	13	-29	-45	-45	N/A
1/31/2020	12	-31	-43	-43	N/A
10/31/2019	14	-26	-41	-40	N/A
7/31/2019	16	-23	-42	-41	N/A
4/30/2019	16	-21	-37	-36	N/A
1/31/2019	18	-13	-34	-32	N/A
10/31/2018	16	-14	5	7	N/A
7/31/2018	12	-16	7	9	N/A
4/30/2018	8	-16	N/A	11	N/A
1/31/2018	4	-19	N/A	14	N/A
10/31/2017	2	-22	N/A	-26	N/A
7/31/2017	1	-21	N/A	-23	N/A
4/30/2017	2	-21	N/A	-24	N/A
1/31/2017	2	-23	N/A	-23	N/A
10/31/2016	2	-18	N/A	-15	N/A
7/31/2016	2	-18	N/A	-15	N/A
4/30/2016	2	-15	N/A	-13	N/A
4/30/2015	2	-9	N/A	-6	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er wordt voorspeld dat KALV de komende 3 jaar winstgevend zal worden, wat wordt beschouwd als een snellere groei dan de spaarquote ( 2.6% ).

Winst versus markt: Er wordt verwacht dat KALV de komende 3 jaar winstgevend zal worden. Dit wordt gezien als een groei die boven het gemiddelde van de markt ligt.

Hoge groeiwinsten: Er wordt verwacht dat KALV binnen 3 jaar winstgevend zal worden.

Omzet versus markt: De omzet van KALV ( 52.4% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.9% per jaar).

Hoge groei-inkomsten: De omzet van KALV ( 52.4% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van KALV naar verwachting over 3 jaar hoog zal zijn

KalVista Pharmaceuticals Toekomstige groei

Future criteriumcontroles 5/6

Belangrijke informatie

Recente toekomstige groei-updates

Forecast to breakeven in 2027

Price target increased by 7.6% to US$20.80

Consensus revenue estimates fall by 58%

Price target decreased to US$21.83

Price target decreased to US$32.83

No longer forecast to breakeven

Recent updates

KalVista Pharmaceuticals, Inc. announced that it expects to receive $5 million in funding from DRI Capital Inc.

KalVista Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $55 million.

KalVista Pharmaceuticals, Inc. Presents New Sebetralstat Data at the 2024 American College of Allergy Asthma and Immunology

KalVista Announces the Submission of Additional Marketing Authorization Applications for Sebetralstat for the Oral On-Demand Treatment of Hereditary Angioedema

Is KalVista Pharmaceuticals (NASDAQ:KALV) In A Good Position To Deliver On Growth Plans?

KalVista Pharmaceuticals: Looking To Be A Major Player In HAE

Kalvista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary Angioedema

KalVista Pharmaceuticals, Inc., Annual General Meeting, Oct 03, 2024

KalVista Pharmaceuticals, Inc. Announces Validation of Marketing Authorization Application by the European Medicines Agency for Sebetralstat for Hereditary Angioedema

KalVista Pharmaceuticals, Inc. Initiates KONFident-KID Trial for On-Demand Treatment of Hereditary Angioedema Attacks with Sebetralstat in Children Aged 2 to 11

Bullish On KalVista Pharmaceuticals: Sebetralstat Nears Approval, Aiming For 2025 Launch

KalVista Pharmaceuticals, Inc. Submits New Drug Application to FDA for Sebetralstat as First Oral On-Demand Treatment for Hereditary Angioedema

KalVista Pharmaceuticals, Inc. Presents Data At Eastern Allergy Conference 2024 and the Japanese Dermatological Association 2024

Kalvista Pharmaceuticals Presents Data on Persisting Unmet Needs in Hereditary Angioedema At the European Academy of Allergy and Clinical Immunology (Eaaci) Congress 2024

Kalvista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating Its Potential to Transform the Treatment Landscape for People with Hereditary Angioedema

CEO & Director exercised options and sold US$258k worth of stock

Forecast to breakeven in 2027

Kalvista Pharmaceuticals, Inc. Appoints William C. Fairey to the Board of Directors

KalVista Pharmaceuticals, Inc. to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas

KalVista Pharmaceuticals, Inc. Announces Board Changes

New minor risk - Share price stability

CEO & Director exercised options and sold US$351k worth of stock

KalVista Pharmaceuticals, Inc. Receives UK Innovation Passport for Sebetralstat from UK Medicines and Healthcare Products Regulatory Agency

KalVista Pharmaceuticals, Inc. Receives UK Innovation Passport for Sebetralstat from UK Medicines and Healthcare Products Regulatory Agency

New minor risk - Shareholder dilution

CEO & Director recently sold US$876k worth of stock

KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

KalVista Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.

KalVista Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $160.125 million.

KalVista: Positive Results From Phase 3 Trial Pave The Way For Commercialization (Downgrade)

Kalvista Pharmaceuticals, Inc. Reports Phase 3 Konfident Trial Meets All Endpoints for Sebetralstat as First Oral On-Demand Therapy for Hereditary Angioedema

We're Keeping An Eye On KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Rate

Chief Scientific Officer notifies of intention to sell stock

Chief Scientific Officer notifies of intention to sell stock

Chief Scientific Officer notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

New major risk - Financial position

CEO & Director exercised options and sold US$122k worth of stock

Price target increased by 7.6% to US$20.80

Kalvista Pharmaceuticals Announces Phase 3 Konfident Trial Milestone Achieved

KalVista Pharmaceuticals to Present Data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology

We're Keeping An Eye On KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Rate

Independent Director notifies of intention to sell stock

CEO & Director exercised options and sold US$160k worth of stock

KalVista Pharmaceuticals, Inc., Annual General Meeting, Sep 26, 2023

KalVista Pharmaceuticals, Inc. Appoints Nicole Sweeny as Chief Commercial Officer

Consensus revenue estimates fall by 58%

KalVista Pharmaceuticals, Inc. Presents New Data at 2023 Meeting of the European Academy of Allergy and Clinical Immunology

CEO & Director exercised options and sold US$57k worth of stock

KalVista Pharmaceuticals, Inc. Presents Data At 13Th C1-Inhibitor Deficiency & Angioedema Workshop

We Think KalVista Pharmaceuticals (NASDAQ:KALV) Needs To Drive Business Growth Carefully

KalVista Pharmaceuticals, Inc. Provides Progress Updates on Sebetralstat Development

Kalvista Pharmaceuticals Announces Publication of Sebetralstat Phase 2 Data in the Lancet

Kalvista Pharmaceuticals Announces Benjamin L. Palleiko Promoted to President

Price target decreased to US$21.83

KalVista Pharmaceuticals Presents Patient-Focused Data at American College of Allergy, Asthma & Immunology (ACAAI) 2022 Meeting

Kalvista Pharmaceuticals Announces Positive Phase 1 Data for Orally Disintegrating Tablet Formulation of Sebetralstat for Use in Hereditary Angioedema

KalVista Pharmaceuticals, Inc. Announces Management Changes

KalVista: Another Setback But The Key Value Driver Is Still In Place

KalVista Pharmaceuticals, Inc. Presents New Patient-Centric Data at 2022 HAEi Global Leadership Workshop

KalVista Pharmaceuticals Announces Termination of KVD824 Phase 2 KOMPLETE Trial for Prophylactic Treatment of Hereditary Angioedema

Price target decreased to US$32.83

Here's Why We're Watching KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Situation

CEO & Director notifies of intention to sell stock

KalVista Pharmaceticals GAAP EPS of -$0.94

Kalvista Pharmaceuticals, Inc. Announces Initiation of KONFIDENT-S Open Label Extension Study for Sebetralstat in Hereditary Angioedema

KalVista Pharmaceuticals, Inc., Annual General Meeting, Oct 13, 2022

KalVista reaches five-month high as rival tumbles on hereditary angioedema